NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Social Phobia—It’s Not About Shyness
Anxiety, Phobias, Psychiatry
2.00 AMA PRA Category 1 Credits™, 2.00 AANP
Learning Objective
Participants will be able to list three factors to consider in the differential diagnosis of social anxiety disorder and outline appropriate pharmacologic and nonpharmacologic management strategies.
Accreditation
This educational program is conceived and credited in accordance with ACCME’s Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute’s Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
| Credits |
Type |
Accreditation Statement |
Designation Statement |
| 2.00 |
AMA PRA Category 1 Credits™ |
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
Pri-Med Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| 2.00 |
AANP |
Pri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308. |
This program has been approved for 2 contact hours of continuing education, which includes 1.0 hours of pharmacology. |
Faculty and Editorial Board
Written By:
Joseph A. Leiberman, MD, MPH, Professor of Family Medicine, Jefferson Medical College, Hockessin, DE;
Reviewed By:
University of Wisconsin School of Medicine and Public Health
Edited By:
Jean Baker, MS, RD, Clinical Editor, Pri-Med Institute, Boston, MA;
Tracy Webb, PhD, Clinical Editor, Pri-Med Institute, Boston, MA;
Financial Disclosure Statement(s)
Dr. Lieberman is a consultant for King Pharmaceuticals, Ortho-McNeil, Pfizer, sanofi-aventis, Sepracor, and Wyeth. He has received honoraria from Sepracor and King Pharmaceuticals.
Dr. Webb holds stock in Millenium.
Ms. Baker has no financial relationships to disclose.
The content collaborators at Imprint Science have no financial relationships to disclose.
Commercial Support:
Forest Pharmaceuticals, Inc.
Pri-Med Disclaimer
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or M|C Communications, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
|
